XNCR stock forecast
Our latest prediction for Xencor, Inc.'s stock price was made on the Jan. 8, 2020 when the stock price was at 36.55$.
In the short term (2weeks), XNCR's stock price should underperform the market by -4.92%. During that period the price should oscillate between -8.50% and +7.28%.
In the medium term (3months), XNCR's stock price should underperform the market by -7.14%. During that period the price should oscillate between -29.78% and +18.77%.Get email alerts
About Xencor, Inc.
Xencor, Inc. engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA.
At the moment the company generates 165M USD in revenues.
On its last earning announcement, the company reported a profit of 0.59$ per share.
The book value per share is 9.30$
Three months stock forecastJan. 8, 2020
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|